Kenya is among nine countries across Africa and Asia where clinical trials will be conducted for a new anti-malarial drug.
Developed by the Swiss pharmaceutical company Novartis, alongside Medicines for Malaria Venture (MMV), the new medicine - known as KAF156 - is aimed at dealing with the tough-to-treat drug-resistant malaria.
...
AllAfrica Subscription Content
You must be an allAfrica.com subscriber for full access to certain content.
You have selected an article from the AllAfrica archive, which requires a subscription. You can subscribe by visiting our subscription page. Or for more information about becoming a subscriber, you can read our subscription and contribution overview.
For information about our premium subscription services:
You can also freely access - without a subscription - hundreds of today's top Africa stories and thousands of recent news articles from our home page »
Already a subscriber? Sign in for full access to article